LTX-Credence shares upgraded by Needham. Human Genome Sciences index chosen as primary endpoint in trials.
Continue to read....
This entry was posted
on Friday, September 4th, 2009 at 10:40 pm and is filed under Zales.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.